Compare · EW vs MYO
EW vs MYO
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Myomo Inc. (MYO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and MYO operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.87B, about 867.9x MYO ($58.6M).
- EW has been more active in the news (7 items in the past 4 weeks vs 2 for MYO).
- EW has more recent analyst coverage (25 ratings vs 3 for MYO).
- Company
- Edwards Lifesciences Corporation
- Myomo Inc.
- Price
- $88.26+0.03%
- $1.46+8.96%
- Market cap
- $50.87B
- $58.6M
- 1M return
- -
- -21.93%
- 1Y return
- -
- +71.68%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2017
- News (4w)
- 7
- 2
- Recent ratings
- 25
- 3
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Latest EW
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
- Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
- SVP, Corporate Controller Dahl Andrew M. sold $49,534 worth of shares (544 units at $91.06), decreasing direct ownership by 4% to 14,868 units (SEC Form 4)
- CVP, EMEACLA Bruls Annette sold $237,907 worth of shares (2,644 units at $89.98), decreasing direct ownership by 13% to 17,984 units (SEC Form 4)
- Edwards Lifesciences Corporation filed SEC Form 8-K: Leadership Update
- CVP, TMTT, Surgical & IHFM Chopra Daveen exercised 31,800 shares at a strike of $72.68 and sold $2,894,440 worth of shares (31,800 units at $91.02) (SEC Form 4)
Latest MYO
- Chief Medical Officer Kovelman Harry sold $19,684 worth of shares (15,488 units at $1.27), decreasing direct ownership by 15% to 90,245 units (SEC Form 4)
- Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Amendment: Chief Medical Officer Kovelman Harry sold $30,329 worth of shares (17,500 units at $1.73), decreasing direct ownership by 14% to 105,733 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry sold $29,896 worth of shares (17,250 units at $1.73), decreasing direct ownership by 14% to 105,983 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 22,457 shares and was granted 55,149 shares, increasing direct ownership by 36% to 123,233 units (SEC Form 4)
- Chief Commercial Officer Mitchell Micah was granted 58,409 shares and covered exercise/tax liability with 21,559 shares, increasing direct ownership by 39% to 130,738 units (SEC Form 4)
- Chief Executive Officer Gudonis Paul R was granted 146,909 shares, increasing direct ownership by 11% to 1,434,679 units (SEC Form 4)
- Chief Financial Officer Henry David A was granted 68,644 shares and covered exercise/tax liability with 25,310 shares, increasing direct ownership by 10% to 470,163 units (SEC Form 4)
- SEC Form S-8 filed by Myomo Inc.
- SEC Form 10-Q filed by Myomo Inc.